All In Biotech

Drug Trial Radar · NCT04836507

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

Mar 2, 2021

Primary completion

Aug 15, 2030

Study completion Sep 26, 2030

Sponsor

Lead sponsor
Curocell Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

Conditions

  • Relapsed Large B-cell Lymphoma
  • Refractory Large B-cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
  • High-grade B-cell Lymphoma
  • Transformed Follicular Lymphoma (TFL)
  • ALL (Acute B-Lymphoblastic Leukemia)

Interventions

  • CRC01Biological

    Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 1.5 x 10\^6 anti-CD19 CAR T cells/kg.

  • FludarabineDrug

    Administered according to package insert

  • CyclophosphamideDrug

    Administered according to package insert

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D)Time frame: 28 days
  2. Phase 2 Pivotal Study: Cohort A : Overall Response Rate (ORR) Cohort B : Overall Complete Remission Rate (OCR)Time frame: 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.